PubMed — Associations of sugar and artificially sweetened soda
with albuminuria and kidney function decline in women.
In two identically designed, parallel, multinational, double - blind studies, researchers tested the potential for atrasentan to further
reduce albuminuria in patients who had both type 2 diabetes and kidney disease and were taking RAS inhibitors.
Dr. de Zeeuw and his colleagues found that the low dose of atrasentan,
lowered albuminuria by 36 % without major side effects.
Agents called renin - angiotensin - system (RAS) inhibitors can reduce both of these; however, patients» risk of experiencing
residual albuminuria remains high.
«Although this study demonstrates that atrasentan treatment results in clinically
significant albuminuria reduction with minimal fluid overload - related or cardiovascular side effects, a larger study on hard renal and / or cardiac outcomes is needed to further support these findings,» said Dr. de Zeeuw.
George L. Bakris, M.D., of University of Chicago Medicine, and colleagues randomly assigned 823 patients (821 received study drug) with diabetes and
elevated albuminuria who were receiving an angiotensin - converting enzyme inhibitor or angiotensin receptor blocker to varying doses of the drug finerenone or placebo.
Association between heme oxygenase - 1 promoter polymorphisms and the development
of albuminuria in type 2 diabetes: a case - control study
An albumin level above the upper limit is called microalbuminuria or
just albuminuria.
In previous research, finerenone
reduced albuminuria in pa ¬ tients with chronic kidney disease and heart failure, with a lower incidence of hyperkalemia (higher than normal levels of potassium in the blood) compared to another medication.
Patients in the study had CKD stages 2 and 3
with albuminuria and were also receiving maximum tolerated doses of RAS inhibitors.
The new work shows the appearance of glucosuria and
albuminuria — both indicators of renal damage — in cats eating high phosphorus diets.
To reduce these risks, it is important to lower blood pressure and urinary protein excretion, or
albuminuria.
Atrasentan, which targets the endothelin receptor A and was initially developed to treat cancer, is known to reduce
albuminuria.
albuminuria is detected as early as 8 weeks of age, progressing to a 10-fold difference by 20 weeks of age
They write that a high protein diet «was not associated with noticeably harmful effects on GFR,
albuminuria, or fluid and electrolyte balance».
Some simply refer to this test as
an albuminuria test.